Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?

European Journal of Internal Medicine

Volumn 24, Issue 3, 2013, Pages 207-212

  Łabuzek, Krzysztof ^a   Kozłowski, Michał ^a   Szkudłapski, Dawid ^a   Sikorska, Patrycja ^a   Kozłowska, Monika ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Dipeptidyl peptidase IV inhibitors; Glucagon like peptide 1; Neoplasms; Pancreatitis; Thyroid gland

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; VILDAGLIPTIN;

CANCER GRADING; CANCER RISK; DOSE RESPONSE; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS POTENTIAL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY CARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PANCREATITIS; PROSTATE CANCER; REVIEW; RHINOPHARYNGITIS; THYROID CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TURNOVER TIME; URINARY TRACT INFECTION;

ANIMALS; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; DRUG TOXICITY; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL AGENTS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN; MODELS, ANIMAL; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PANCREAS; PANCREATIC DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RISK FACTORS;

EID: 84875221537     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.01.009     Document Type: Review

References (84)

1. D.J. Drucker The biology of incretin hormones Cell Metab 3 2006 153 165
2. M.A. Nauck, F. Stöckmann, R. Ebert, and W. Creutzfeldt Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 29 1986 46 54
3. L.T. Shuster, V.L.W. Go, R.A. Rizza, P.C. O'Brien, and F.J. Service Incretin effect due to increased secretion and decreased clearance of insulin in normal humans Diabetes 37 1988 200 203
4. H. Tillil, E.T. Shapiro, A. Miller, T. Karrison, B.H. Frank, and J.A. Galloway Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans Am J Physiol 254 1988 E349 E357
5. E.T. Shapiro, H. Tillil, A. Miller, B.H. Frank, J.A. Galloway, and A.H. Rubenstein Insulin secretion and clearance: comparison after oral and intravenous glucose Diabetes 36 1987 1365 1371
6. C.F. Deacon Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Diabetes Obes Metab 9 2007 23 31
7. L.L. Kjems, J.J. Holst, A. Volund, and S. Madsbad The influence of GLP-1 on glucose stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and non-diabetic subjects Diabetes 52 2003 380 386
8. J. Buteau, S. Foisy, E. Joly, and M. Prentki Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptors Diabetes 52 2003 124 132
9. D.J. Drucker Glucagon-like peptides: regulators of cell proliferation, differentation and apoptosis Mol Endocrinol 17 2003 161 171
10. L. Farilla, A. Bulotta, B. Hirshberg, S. Li Calzi, N. Khoury, and H. Noushmehr Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 144 2003 5149 5158
11. K.P. Knoch, R. Meisterfeld, S. Kersting, H. Bergert, A. Altkrüger, and C. Wegbrod cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in β cells Cell Metab 3 2006 123 134
12. R. Kodera, K. Shikata, H.U. Kataoka, T. Takatsuka, S. Miyamoto, and M. Sasaki Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes Diabetologia 54 2011 965 978
13. M. Gutniak, C. Orskov, J.J. Holst, B. Ahrén, and S. Efendic Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus N Engl J Med 326 1992 1316 1322
14. K.B. Degn, C.B. Juhl, J. Sturis, G. Jakobsen, B. Brock, and V. Chandramouli One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and a- and b-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 2004 1187 1194
15. J.J. Meier, B. Galwitz, N. Siepmann, J.J. Holst, C.F. Deacon, and W.E. Schmidt Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia Diabetologia 46 2003 798 801
16. M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, and W. Creutzfeldt Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744
17. V.R. Aroda, and R. Ratner The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review Diabetes Metab Res Rev 27 2011 528 542
18. J.H. Best, B.J. Hoogwerf, W.H. Herman, E.M. Pelletier, D.B. Smith, and M. Wenten Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the GLP-1 receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database Diabetes Care 34 2011 90 95
19. S. Ogawa, M. Ishiki, K. Nako, M. Okamura, M. Senda, and T. Mori Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes Tohoku J Exp Med 223 2010 133 135
20. B.P. Pacheco, R.O. Crajoinas, G.K. Couto, A.P. Davel, L.M. Lessa, and L.V. Rossoni Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats J Hypertens 29 2011 520 528
21. A. Marney, S. Kunchakarra, L. Byrne, and N.J. Brown Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans Hypertension 56 2010 728 733
22. N.J. Brown, S. Byiers, D. Carr, M. Maldonaldo, and B.A. Warner Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema Hypertension 54 2009 516 523
23. D.J. Drucker, and A.B. Goldfine Cardiovascular safety and diabetes drug development Lancet 377 2011 977 979
24. C.F. Deacon, M.A. Nauck, M. Toft-Nielsen, L. Pridal, B. Willms, and J.J. Holst Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1995 1126 1131
25. I. Salcedo, D. Tweedie, Y. Li, and N.H. Greig Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders Br J Pharmacol 166 2012 1586 1599
26. G.G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, and R.P. Shannon Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 2006 694 699
27. G.G. Sokos, H. Bolukoglu, J. German, T. Hentosz, G.J. Magovern Jr. , and T.D. Maher Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting Am J Cardiol 100 2007 824 882
28. M. Elashoff, A. Matveyenko, B. Gier, R. Elashoff, and P. Butler Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1 based therapies Gastroenterology 141 2011 150 156
29. J.S. Nachnani, D.G. Bulchandani, A. Nookala, B. Herndon, A. Molteni, and P. Pandya Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas Diabetologia 53 2010 153 159
30. B. Gier, A. Matveyenko, D. Kirakossian, D. Dawson, S. Dry, and P. Butler Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras G12D mouse model Diabetes 61 2012 1250 1262
31. A. Matveyenko, S. Dry, H. Cox, A. Moshtaghian, T. Gurlo, and R. Galasso Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes Diabetes 58 2009 1604 1615
32. A.V. Matveyenko, S. Dry, H.I. Cox, A. Moshtaghian, T. Gurlo, and R. Galasso Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes Diabetes 58 2009 1604 1615
33. I. Parsa, D.S. Longnecker, D.G. Scarpelli, P. Pour, J.K. Reddy, and M. Lefkowitz Ductal metaplasia of human exocrine pancreas and its association with carcinoma Cancer Res 45 1985 1285 1290
34. D.E. Bockman, W.R. Boydston, and M.C. Anderson Origin of tubular complexes in human acute pancreatitis Am J Surg 144 1982 243 249
35. M. Wagner, F.R. Greten, C.K. Weber, S. Koschnick, T. Mattfeldt, and W. Deppert A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease Genes Dev 15 2001 286 293
36. S.S. Engel, D.E. Williams-Herman, G.T. Golm, R.J. Clay, S.V. Machotka, and K.D. Kaufman Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis Int J Clin Pract 64 2010 984 990
37. O. Strobel, D.E. Rosow, E.Y. Rakhlin, G.Y. Lauwers, A.G. Trainor, and J. Alsina Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia Gastroenterology 138 2010 1166 1177
38. P.S. Denker, and P.E. Dimarco Exenatide (Exendin-4) - induced pancreatitis: a case report Diabetes Care 26 2006 471
39. FDA safety alert http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm150839.htm
40. FDA safety alert http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm183800.htm
41. C.J. Currie, C.D. Poole, and E.A. Gale The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 2009 1766 1777
42. S. Shetty, K. Secnik, and A.K. Oglesby Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes J Manag Care Pharm 11 2005 559 564
43. D. Li, S.C. Yeung, M.M. Hassan, M. Konopleva, and J.L. Abbruzzese Anti-diabetic therapies affect risk of pancreatic cancer Gastroenterology 137 2009 482 488
44. M. Monami, I. Dicembrini, D. Martelli, and E. Mannucci Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials Curr Med Res Opin 27 2011 57 64
45. B. Gier, P.C. Butler, C.K. Lai, D. Kirakossian, M.M. DeNicola, and M.W. Yeh Glucagon like peptide-1 expression in the human thyroid gland J Clin Endocrinol Metab 97 2012 121 131
46. L. Bjerre Knudsen, L.W. Madsen, S. Andersen, K. Almholt, A.S. de Boer, and D.J. Drucker Glucagon like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 151 2010 1473 1486
47. Victoza (liraglutide injection) http://www.fda.gov/downloads/ AdvisoryCommittees/Committees%20MeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM151129.pdf
48. L.W. Madsen, J.A. Knauf, C. Gotfredsen, A. Pilling, I. Sjögren, and S. Andersen GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation Endocrinology 153 2012 1538 1547
49. T. Stulc, and A. Sedo Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 88 2010 125 131
50. J.A. Koehler, T. Kain, and D.J. Drucker Glucagon-like-peptide 1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells Endocrinology 152 2011 3362 3372
51. K. Masur, F. Schwartz, F. Entschalden, B. Niggemann, and K.S. Zaenker DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells Regul Pept 137 2006 147 155
52. D.G. Munroe, A.K. Gupta, F. Kooshesh, T.B. Vyas, G. Rizkalla, and H. Wang Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2 Proc Natl Acad Sci U S A 96 1999 1569 1573
53. P.A. Havre, M. Abe, Y. Urasaki, K. Ohnuma, C. Morimoto, and N.H. Dang The role of CD26/dipeptidil peptidase IV in cancer Front Biosci 13 2008 1634 1645
54. P. Busek, R. Malik, and A. Sedo Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer Int J Biochem Cell Biol 36 2004 408 421
55. H. Kajiyama, F. Kikkawa, T. Suzuki, K. Shibata, K. Ino, and S. Mizutani Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma Cancer Res 62 2002 2753 2757
56. C.L. Pethiyagoda, D.R. Welch, and T.P. Fleming Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells Clin Exp Metastasis 18 2000 391 400
57. H. Kajiyama, F. Kikkawa, E. Khin, K. Shibata, K. Ino, and S. Mizutani Dipeptidyl peptidase overexpression induces upregulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells Cancer Res 63 2003 2278 2283
58. E.E. Khin, F. Kikkawa, K. Ino, H. Kajiyama, T. Suzuki, and K. Shibata Dipeptidyl peptidase IV expression in endometrial endometroid adenocarcinoma and its inverse correlation with tumor grade Am J Obstet Gynecol 188 2003 670 676
59. M.E. Morrison, S. Vijayasaradhi, D. Engelstein, A.P. Albino, and A.N. Houghton A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase J Exp Med 177 1993 1135 1143
60. U.V. Wesley, M. McGroarty, and A. Homoyouni Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway Cancer Res 65 2005 1325 1334
61. D.T. Price, G.D. Rocca, C. Guo, M.S. Ballo, D.A. Schwinn, and L.M. Luttrell Activation of extracellular signal-regulated kinase in human prostate cancer J Urol 162 1999 1537 1542
62. U.V. Wesley, S. Tiwari, and A.N. Houghton Role of dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells Int J Cancer 109 2004 855 866
63. A. Carbone, M. Cozzi, A. Gloghini, and A. Pinto CD26/dipeptidyl peptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cell and subset of T-cell non-Hodkin's lymphomas Hum Pathol 25 1994 1360 1365
64. O.J. Cordero, D. Ayude, M. Nogueira, F.J. Rodriguez-Berrocal, and M.P. de la Cadena Preoperative serum CD26 levels: diagnostic efficency and predictive value for colorectal cancer Br J Cancer 83 2000 1139 1146
65. A.A. Gumbs Obesity, pancreatitis and pancreatic cancer Obes Surg 18 2008 1183 1187
66. A.E. Butler, R. Galasso, A. Matveyenko, R.A. Rizza, S. Dry, and P.C. Butler Pancreatic duct replication is increased with obesity and type 2 diabetes in humans Diabetologia 53 2010 21 26
67. R. Perfetti, J. Zhou, E.D. Maire, and J.M. Egan Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats Endocrinology 141 2000 4600 4605
68. J. Jonsson, L. Carlsson, T. Edlund, and H. Edlund Insulin-promoter- factor-1 is required for pancreas development in mice Nature 371 1994 606 609
69. J.F. Habener, and D.A. Stoffers A newly discovered role of transcription factors involved in pancreatic development and the pathogenesis of type 2 diabetes mellitus Proc Assoc Am Physicians 110 1998 12 21
70. G. Xu, D.A. Stoffers, J.F. Habener, and S. Bonner-Weir Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276
71. P.L. Brubaker, and D.J. Drucker Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Endocrinology 145 2004 2653 2659
72. S. Jančík, J. Drábek, D. Radzioch, and M. Hajdúch Clinical Relevance of KRAS in Human Cancers J Biomed Biotechnol 2010 2010 10.1155/2010/150960 [Article ID 150960, 13 pages].
73. D.M. Kendall, M.C. Riddle, J. Rosenstock, D. Zhuang, D.D. Kim, and M.S. Fineman Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 28 2005 1083 1091
74. R.J. Heine, L.F. Van Gaal, D. Johns, M.J. Mihm, M.H. Widel, and R.G. Brodows Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 143 2005 559 569
75. J.B. Buse, R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 27 2004 2628 2635
76. R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 2005 1092 1100
77. B. Zinman, B.J. Hoogwerf, S. Durán García, D.R. Milton, J.M. Giaconia, and D.D. Kim The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 146 2007 477 485
78. D. Kim, L. MacConell, D. Zhuang, P.A. Kothare, M. Trautmann, and M. Fineman Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30 2007 1487 1493
79. R.E. Amori, J. Lau, and A.G. Pittas Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 298 2007 194 206
80. B. Richter, E. Bandeira-Echtler, K. Bergerhoff, and C.L. Lerch Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Cochrane Database Syst Rev 2008 CD006739
81. D. Williams-Herman, S.S. Engel, E. Round, J. Johnson, G.T. Golm, and H. Guo Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes BMC Endocr Disord 10 2010 7
82. M. Ligueros-Saylan, J.E. Foley, A. Schweizer, A. Couturier, and W. Kothny An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and II clinical trials Diabetes Obes Metab 12 2010 495 509
83. R. Mentlein Dipeptidyl-peptidase IV, (CD26): role in the inactivation of regulatory peptides Regul Pept 85 1999 9 24
84. D.J. Drucker Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action Diabetes Care 30 2007 1335 1343